희귀의약품 개발전략-Vertex Pharmaceutical strategy

목차

1. Executive Summary
2. Issue Statement
3. Background
4. Capabilities
5. Recommendations
6. Implementation
7. Conclusion
8. References
9. Appendix

본문내용

Executive Summary
Vertex Pharmaceuticals, a Boston-based biopharmaceutical company, seeks to develop drug therapies for critically unmet diseases to create significant improvement in patients’ health. Currently, their only major drugs on the market treat patients with Cystic Fibrosis. However, in order for Vertex to compete against larger pharmaceutical companies, they will have to create and implement a strategy for sustainable growth. By expanding indications for the current Cystic Fibrosis (CF) therapeutic area and developing follow-on drugs to improve these therapies’ efficacy, Vertex can solidify and expand their market share within the CF space. Furthermore, through diverse pipeline developments and considering novel orphan disease targets, such as Batten disease, they may continue to grow in novel new therapeutic areas. In order to explore a new orphan disease market, we considered several factors. First, there should be no cure or current effective treatment.

참고 자료

Werth, Barry. The Billion-Dollar Molecule: One Company’s Quest for the Perfect Drug. Simon & Schuster New York © 1994.
Company Profile: Vertex Pharmaceuticals Incorporated. Marketline. 12 Feb 2016
Vertex Pharmaceuticals, Inc. (2016) 2015-2016 Annual Report. Boston, MA.
Cystic Fibrosis Foundation. “Drug Development Pipeline.” Visited: 04 Mar 2016 <https://tools.cff.org/research/drugdevelopmentpipeline/>
Cystic Fibrosis Foundation. “What is CF?” Visited 04 Mar 2016 <https://www.cff.org/What-is-CF/About-Cystic-Fibrosis/>
“Vertex Pharmaceuticals Inc.” MSN Money. Visited 04 Mar 2016 <http://www.msn.com/en-us/money/stockdetails?symbol=US:VRTX>
McGraw, Ben. “Reversing the Traditional Drug Development Model.” PerkinElmer, Inc. © 2015
“Orphan Drug Report 2015.” Evaluate Pharma © October 2015
Smith, Ian. “Vertex Pharmaceuticals.” Credit Suisse, Healthcare Conference. 10 Nov 2015.
Smith, Ian. “Vertex Pharmaceuticals.” JP Morgan Healthcare Conference. 11 Jan 2016.
Smith, Ian. (23 Feb 2016). Telephone Interview.
Vertex Pharmaceuticals, Inc. (2015) 2014-2015 Annual Report. Boston, MA.
“Search Orphan Drug Designations and Approvals.” FDA. Visited 04 Mar 2016. <http://www.accessdata.fda.gov/scripts/opdlisting/oopd/OOPD_Results_2.cfm>
Cryanoski, David. Reardon, Sara. “Chinese scientists genetically modify human embryos.” Nature. Visited 04 Mar 2016. <http://www.nature.com/news/chinese-scientists-genetically-modify-human-embryos-1.17378>
Cooper, Jonathan. “Moving towards therapies for Juvenile Batten disease.” Experimental Neurology 211: 2, 329-331.
Vertex Pharmaceuticals, Inc. (1991) 1990-1991 Annual Report. Boston, MA.
Lyons, Karen. “New Cystic Fibrosis Treatments May Significantly Increase Pharmacy Benefit Costs.” Prime Therapeutics. 06 Apr 2016